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Background: Autologous transplantation of modified mesenchymal stem cells (MSCs) is a promising candidate for
the treatment of the refractory clinical disease, avascular necrosis of the femoral head (ANFH). Our previous
attempts by compounding MSCs with medical fibrin glue to treat ANFH in animal model have achieved excellent
effects. However, the underlying molecular mechanism is unclear, especially on the transgenic gene expression.
Methods: Rabbit MSCs were isolated and compounded with fibrin glue. Following degrading of fibrin glue,
proliferation, viability, expression of transgenic hepatocyte growth factor gene as well as osteogenic differentiation
of MSCs were evaluated together with that of uncompounded MSCs. Fibrin glue-compounded MSCs were
transplanted into the lesion of ANFH model, and the therapeutic efficacy was compared with uncompounded
MSCs. One-Way ANOVA was used to determine the statistical significance among treatment groups.
Results: Fibrin glue compounding will not affect molecular activities of MSCs, including hepatocyte growth factor
(HGF) secretion, cell proliferation and viability, and osteogenic differentiation in vitro. When applying fibrin
glue-compounded MSCs for the therapy of ANFH in vivo, fibrin glue functioned as a drug delivery system and
provided a sustaining microenvironment for MSCs which helped the relatively long-term secretion of HGF in the
femoral head lesion and resulted in improved therapeutic efficacy when compared with uncompounded MSCs as
indicated by hematoxylin-eosin staining and immunohistochemistry of osteocalcin, CD105 and HGF.
Conclusion: Transplantation of fibrin glue-compounding MSCs is a promising novel method for ANFH therapy.
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Osteogenic regenerationBackground
As an irreversibly progressive pathological process, avas-
cular necrosis of the femoral head (ANFH) is regarded
as an immortal and incurable disease which mainly af-
flicts people under 40-year-old [1-3]. Mesenchymal stem
cells (MSCs)-based treatments are believed to be a
promising method for ANFH therapy due to the osteo-
genic potential of MSCs and the convenience of prepar-
ation [4], and have been applied for therapy of ischemic* Correspondence: maryhmz@126.com
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unless otherwise stated.diseases such as ANFH [5-7] and myocardial infarction
[8,9] with satisfactory effects.
Medical fibrin glue is a biopolymer matrix composed
by human natural fibrinogen and thrombin. Fibrin glue
is commonly used for surgical hemostasis and tissue
sealing as a sealant [10-12]. In recent years it has been
applied as supporting material for cell growth, migration,
and differentiation [13,14]. Fibrin glue can also be used
as the cell delivery system in tissue engineering [15-17],
such as construction of an injectable tissue-engineered
bone graft, or as the drug delivery system in various
drug therapies [18-20]. The advantages of clinical appli-
cation of fibrin glue were widely studied, yet the detailedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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ation, such as long-term sustainable effects in MSCs-
medicated treatments.
We previously reported the significant effects of
adenoviral vector-based hepatocyte growth factor (Ad-
HGF)-transfected MSC treatments using the model of
hormone ANFH in which MSCs have ever been com-
pounded with a supportive fibrin glue delivery mixture
and applied in the local ANFH lesion region [21]. How-
ever, in a short-term observation period of 4 weeks post
treatment, there was no significant difference in the re-
covery efficacy regardless of whether using compounded
or uncompounded MSCs, and also the effects of fibrin
glue on MSCs activity was not evaluated.
In this work, we systemically compared the therapeutic
efficacy of HGF-transgenic MSCs by compounded or
uncompounded with fibrin glue and extended the obser-
vation time to as long as 8 weeks following treatment.
Here, we showed the evidences of the molecular effects
and mechanism of fibrin glue-compounded MSCs in im-
proving the effects of ANFH therapy, which may im-
prove our understanding of the role of fibrin glue in
MSC treatment of ANFH and shade light on the gener-
ation of better therapeutic regime.
Materials and methods
Preparation and differentiation of BMSCs
Allogeneic MSCs were prepared, identified and transfected
with Adenovirus vectors as described before [21]. For iden-
tification and differentiation assays of BMSCs, cells were
induced to differentiate into osteoblasts, chondroblasts and
adipocytes separately, by culturing cells in corresponding
induction media (Cyagen Biosciences Inc., Goleta, CA).
The differentiation characteristics were detected using
NBT-BCIP Alkaline Phosphatase Color Development Kit
(Beyotime Institute of Biotechnology, Shanghai, China)
and Alizarin Red Sulfate (ARS) staining (Cyagen) for
osteogenic differentiation, Alcian blue staining (Cyagen)
for chondrogenic differentiation and Oil Red O staining
(Cyagen) for adipogenic differentiation according to the
instruction of the manufactures.
Preparation of transfected BMSCs compounding with
medical fibrin glue
For compounding with fibrin glue, Ad-HGF or Ad-GFP-
transfected MSCs were collected 48 h later. Two compo-
nent solutions of fibrin glue were prepared separately.
In solution I, freeze-dried human fibrinogen (Shanghai
RAAS Blood Products Co. Ltd., Shanghai, China) was
dissolved to 80 mg/mL with 2000 KIU/mL aprotinin in
sterile water (Lanzhou Dadeli Biochemical Pharmaceut-
ical Co. Ltd., Lanzhou, China) at 37°C. In solution II,
thrombin (Jin Kang Pharmaceutical Co. Ltd., Nanjing,
China) was dissolved to 400 IU/mL with 40 mmol/L ofCaCl2 in sterile water. For in vitro assays, 2 × 10
4 cell pel-
let was first resuspended with 180 μL of solution I, and
quickly mixed with 20 μL of solution II in one well of
24-well plates (Nunc, Thermo Fisher Scientific, Waltham,
MA). The MSC-fibrin glue composite was cultured and
observed for 1 week. For ANFH therapy in vivo, a duplex
syringe was used to transfer 90 μL of solution I containing
1 × 106 transfected MSCs and 10 μL of solution II into the
lesions through the tunnel of the core decompression as
described previously [21].
Scanning electron microscopy (SEM) sample preparation
and observation
For SEM observation, fibrin glue composites containing
MSCs were cut into small pieces and fixed with pre-cold
fresh 2.5% glutaraldehyde-0.1 M PBS (pH7.4) at 4°C for
1 h. Following wash 3 times with PBS, samples were
post-fixed with 1% osmium tetroxide-0.1 M PBS for
30 min and stained with 1% tannic acid-0.1 M PBS for
30 min. After dehydration through gradient concentra-
tion of ethanol, the specimens were dried at critical
point and coated with gold by ion sputter, and observed
with S-3000 N scanning electron microscope (Hitachi,
Hitachi, JP).
HGF ELISA
To assay HGF secretion by MSCs compounded with fi-
brin glue, one week after compounding, fibrin glue was
dissolved using 1600 U/mg of bovine pancreas trypsin
(Calbiochem, La Jolla, CA) at 37°C. Cells released from
fibrin glue composite were cultured for 24 h, and the
HGF secretion in the supernatant was analyzed using an
ELISA kit (BioSource International, Inc., Camarillo, CA)
as per the manufacturer’s instruction. Results were read
at 450 nm wavelength using a Varioskan Flash micro-
plate reader (Thermo Fisher Scientific).
Cell proliferation and viability assays
The proliferation activity and viability of MSCs compound-
ing with or without fibrin glue were assayed using the
Cell-Light™ EdU DNA Cell Proliferation Kit (Guangzhou
Ribobio Co., Ltd, Guangzhou, China) and the Cell Count-
ing Kit-8 (CCK-8, Dojindo Laboratorise, Tokyo, Japan) ac-
cording to the manufacturer’s instruction and as described
before [22].
Animal surgery and MSC injection
Thirty New Zealand rabbits were maintained under spe-
cific pathogen-free conditions in The Experimental Animal
Center of Nanfang Hospital (Guangzhou, China) and ran-
domly assigned to 4 groups with the approve of the Animal
Ethics Committee at Southern Medical University. Normal
group included 5 animals untreated, while horse serum
(Hyclone) and prednisolone acetate (Pharmacia & Upjohn
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hormone ANFH in the remaining 25 animals as previously
described [23]. Model group contained 5 rabbits with
untreated ANFH. The remaining animals were sepa-
rated evenly to 2 groups to receive treatment of HGF-
transgenic MSC transplantation compounded with fibrin
glue (HGF/MSCs + FG) or uncompounded (HGF/MSCs)
as described previously [22]. To further demonstrate the
activities of HGF-transgenic MSCs, the efficacy was fur-
ther compared with another four treatments: FG only
(FG), HGF-transgenic fibroblasts compounded with fibrin
glue (HGF/Fibroblasts + FG), GFP-transgenic MSCs com-
pounded with fibrin glue (GFP/MSCs + FG) and HGF-
transgenic osteoblasts compounded with fibrin glue (HGF/
OB + FG). Animals all survived during the observation
periods and femoral head samples were obtained follow-
ing air-euthanasia at 4 and 8 weeks post-treatment. Paraf-
fin embedded-samples and sections were assayed with
hematoxylin-eosin (HE) staining and immunohistochemis-
try with the following antibodies: osteocalcin (OCN)
(OCG4; Abcam plc., Cambridge, UK; 1:100), CD105 (SN6h;
Invitrogen co. Ltd., CA, USA; 1:75), and HGF (BOSTER
Bioengineering Co. Ltd., Wuhan, China; 1:250), p-ERK1/2
(E-4; 1:250), p-Akt (D9E; Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA, USA; 1:250). Pictures were taken with mi-
croscopy (Nikon), while the number of empty lacunae and
hematopoietic medullary cells as well as the integrated op-
tical density (IOD) in 10 random fields per section was ana-
lyzed with Image-Pro Plus software version 6.0 (IPP 6.0,Figure 1 Identification of multi-potential differentiation of MSCs and
cultured and induced to differentiate into osteoblasts indicated by staining
(C) and adipocytes by Oil Red O (D). (E) After fibrin glue-compounding wi
fluorescence resulting from Ad-HGF transfection indicated the cell activity.
glue were observed with the scanning electric microscopy.Media Cybernetics, Inc., MD). Three sections per animal
were analyzed. Calculation of IOD was carried out accord-
ing to the instruction of the software. After lining out posi-
tive staining areas in the sections, the area and the color
depth were synthetically calculated by the software.
Statistical analysis
Data were expressed as the mean ± se. Statistical signifi-
cance was set at P < 0.05 determined by One-Way
ANOVA using SPSS statistical software version 16.0
(SPSS, Chicago, IL). Post hoc multiple comparisons were
done with least Significant Difference or Dunnett’s T3.
Results
Characterization of MSCs and morphology in
compounded fibrin glue
First, we isolated MSCs and determined their multi-potent
abilities by differentiating into osteoblasts, chondroblasts
and adipocytes (Figure 1A-D). Qualified MSCs were then
transfected with Ad-HGF and compounded with fibrin
glue. Pseudopods of GFP-expressing MSCs in the fibrin
glue composite could be clearly observed under micro-
scope, suggesting the healthy state of these compounded
cells (Figure 1E). The MSCs extended on the surface of fi-
brin glue composite with normal morphology as shown by
SEM, while internal cells mainly displayed a sphere pheno-
type with abundant surface villi commonly seen on healthy
cells (Figure 1F). These results suggest that fibrin glue-
compounded cells can survive and remain healthy.observation of MSCs compounded with fibrin glue. Cells were
of Alizarin Red (A) and NBT-BCIP (B), chondroblasts by Alcian blue
thin one week, normal cell shape under bright field and green
(F) The morphologies of cells on the surface of and inside the fibrin
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biological activities as uncompounded transgenic MSCs in
short-term in vitro culture
To assess the effects of MSCs compounded with fibrin
glue, we evaluated the proliferation and osteogenic differ-
entiation in vitro. After dissolving the fibrin glue compo-
nent of the MSC-fibrin glue complex one week later, the
biological activity of compounded MSCs was determined
and compared with uncompounded MSCs. The results of
EdU incorporation and WST-8 assays showed that MSCs
from the MSC-fibrin glue complex have a high prolifera-
tion rate similar as uncompounded MSCs resulting from
the expression of HGF transgene (Figure 2A-C). The ex-
pression level of secreted HGF from transgenic MSCs was
assayed using ELISA at 24 h after MSCs released from
fibrin glue. The results showed that transgenic MSCsFigure 2 Proliferation, HGF expression and osteoblast differentiation
viability were assayed using EdU incorporation (A, B) and CCK-8 method (C
differentiation of MSCs compounded with or without fibrin glue was assay
with osteogenic culture medium.expressed similar level of secreted HGF no matter ever
compounded with or without fibrin glue (Figure 2D).
Moreover, MSCs from fibrin glue composite exhibited
similar osteogenic differentiation ability as uncompounded
MSCs, which was showed by ALP expression (Figure 2E)
and alizarin red (ARS) staining (Figure 2F, G). The above
results suggested that short-term compounding with fibrin
glue will not change the biological activities of MSCs in
osteogenic differentiation and responsive sensitivity to
HGF stimulation.
Fibrin glue composite improved the therapeutic effects of
HGF-transgenic MSCs on ANFH
After the ANFH model was established, the animals were
given MSCs or MSCs + FG treatment. Similar as previous
report, there is no significant difference could be observedof MSCs compounded with fibrin glue. Cell proliferation and
). HGF expression was assayed using ELISA (D). Osteoblast
ed using ALP staining (E) and ARS staining (F, G) after treatment
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while obvious and similar therapeutic effects were observed
in both treatment groups within 4 weeks [21]. However,
the MSCs + FG group exhibited more significant improve-
ment in recovery from ANFH when the observation
period was extended to 8 weeks. Results of HE staining
indicated that hematopoietic cells in the MSCs + FG
group increased more significantly than that of the MSCs
group and the number of empty lacuna was dramatically
decreased in the MSCs + FG group compared with the
MSCs group (P < 0.05) (Figure 3). The above results
suggested better angiogenesis and formation of osteo-
genic microenvironment in MSCs + FG group during
tissue repairing.
As a specific marker of bone formation during bone
turnover, OCN could be used to characterize the initial
osteogenic differentiation of MSCs [24,25]. In addition,
OCN was mainly expressed in perivascular vessels and
part of osteocytes in normal tissues. In ANFH model,
expression of OCN was almost lost completely. Such
loss could be rescued by transplantation of Ad-HGF
transfected MSCs regardless of the presence of fibrin
glue in short-term treatment. However, the significant
differences only could be clearly observed at the end of
8 weeks post treatment, OCN levels in the MSCs + FGFigure 3 Histopathological assessment of treatment efficacy with MS
transplantation, HE staining results of histological examination (A) were sem
empty lacunae in the trabeculae (C). n = 15 or 30/group (3 sections/animal
versus the MSCs + FG group.group was significantly higher than that in the MSCs
group (P < 0.05) (Figure 4A, B). As expected, transplant-
ation of HGF transgenic MSCs restored the vascularization
of the femoral head indicated by the expression of CD105,
the marker of newly-formed blood vessels [26,27]. Notably,
the level of CD105 in the MSCs + FG group was also higher
than that in the MSCs group (P < 0.05) at 8 weeks after
MSC transplantation (Figure 4C, D). These results sug-
gested that the duration of the MSC activity and the secre-
tion of HGF were longer in the MSCs + FG group than that
in the uncompounded MSCs group.
Significant improvement of ANFH defects compared
with the FG group and the fibroblasts + FG group (P < 0.05)
further demonstrated the effect of MSCs in the recovery of
ANFH. Even being treated with osteoblasts combined with
fibrin glue (the OB + FG group), the alleviation of ANFH
symptom was also not equivalent as that in the MSCs + FG
group which may be owing to the lack of vascularization
activity by osteoblasts (Figures 3, 4).
Sustaining expression of HGF and activation of signaling
pathways contributed to the therapeutic effects
To explore underlying mechanism, we detected HGF and
downstream signaling molecules in the local regions. Con-
sistently, the local expression of HGF was already higher inCs for hormone-induced ANFH. Eigth weeks after MSC
i-quantified for hematopoietic tissue in the medullary cavity (B) and
, 5 or 10 animals/group). *, P < 0.05 versus the ANFH group. #, P < 0.05
Figure 4 Immunohistochemical detection and semi-quantification of in vivo OCN and CD105 expression. OCN (A, B) and CD105 (C, D)
expression were assayed following induction of hormone-induced ANFH and 8 weeks after treatment with transplantation of MSCs. n = 15 or
30/group (3 sections/animal, 5 or 10 animals/group). *, P < 0.05 versus the ANFH group. #, P < 0.05 versus the MSCs + FG group.
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by the end of 4 weeks post treatment. This situation of
higher expression of HGF in MSCs + FG group was main-
tained until the end of 8 weeks post treatment (Figure 5),
which was consistent with better therapeutic effects
achieved in the MSCs + FG group. ERK- and Akt-mediated
signaling pathways are downstream of HGF stimulation
[28] and their crosstalk contribute the fine-tune regulation
of osteogenesis. Our previous results showed that dosage
variation of local HGF levels could significantly affect the
activation of the downstream ERK and Akt signaling path-
ways, and consequently regulate the proliferation and dif-
ferentiation of MSCs as well as MSC-mediated osteogenic
differentiation during the treatment of ANFH [22]. There-
fore, the activation levels of ERK and Akt signalingpathways were compared between the MSCs group and the
MSCs + FG group. IHC staining showed similar level of
ERK1/2 signaling activation between the two transgenic
MSC-transplanted groups by the end of 4 weeks post treat-
ment. The difference appeared between 4 to 8 weeks. In
the MSCs group, the level of ERK1/2 activation fell signifi-
cantly compared with that by the end of 4 weeks (P < 0.05).
However, sustained activation of ERK1/2 was observed
in the MSCs + FG group at 4 weeks and 8 weeks post treat-
ment. As expected, the activation level of Akt pathway
was decreased in the MSCs group significantly at 8 weeks
compared with 4 weeks, while the level of Akt activation
was maintained in the MSCs + FG group. In short, al-
though HGF-secreting MSCs in the MSCs group contrib-
uted significantly to the recovery of local ANFH lesion,
Figure 5 Immunohistochemical detection and semi-quantification of in vivo HGF expression, p-ERK1/2 and p-Akt. HGF expression (A),
phosphorylation of ERK1/2 (p-ERK1/2) (B) and Akt (p-Akt) (C) were assayed at 4 and 8 weeks after treatment of hormone-induced ANFH with
transplantation of MSCs. n = 15 or 30/group (3 sections/animal, 5 or 10 animals/group). *, P < 0.05 versus the ANFH group; #, P < 0.05 versus
between the MSCs group and the MSCs + FG group (A); **, P < 0.05 versus between 4 and 8 weeks (B, C).
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longer survival period of MSCs and result in prolonged
HGF secretion time which provide more sustainable and
effective therapeutic effects in treatment of ANFH.
Discussion
In this study, the biological characteristics of MSCs after
compounded with medical fibrin glue were compared
with that of uncompounded MSCs in vitro and in vivo.
Our results demonstrated that Ad-HGF-transfected MSCscompounded with fibrin glue not only prevented the loss
of MSCs after the long-term (about 8 weeks) in vivo treat-
ment in the femoral head but also allowed the prolonged
and gradual release of HGF expressed by transgenic MSCs
to improve the proliferation and osteogenesis of MSCs
which contributed the ANFH therapy in vivo.
The characteristics and clinical usage of fibrin glue have
been widely investigated and reviewed [29]. Although
fibrin glue has been used as a cell delivery system, its
effect on the activity of transgenic MSCs has not been
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could maintain the healthy state of MSCs as uncom-
pounded MSCs which was supported by live cell imaging
and SEM observation showing the imbedded MSCs with
abundant surface villi of sphere MSCs. In vitro assays
showed that MSCs released from MSC-fibrin glue complex
exhibited similar levels of HGF secretion, proliferation and
osteogenic differentiation compared with uncompounded
MSCs. Thus, fibrin glue compounding, as a physical cell
delivery system, could completely maintain the full bio-
logical characteristics of MSCs.
Short-term in vivo assays showed that fibrin glue com-
pounding or non-compounding displayed no significant
differences in therapeutic efficacy by the end of 4-week
treatment. However, the differential therapeutic effects
were apparent that the MSCs + FG group exhibited more
significant advantages than those uncompounded groups
when the treatment period was extended to 8 weeks. The
better therapeutic capacity of MSCs + FG group was dem-
onstrated by more hematopoietic medullary cells and less
empty lacunae formation as showed by H&E staining.
And elevated expression of OCN and CD105 indicated
the improvement of osteogenesis and haemopoiesis. It
was supposed that the better performance of MSCs + FG
group resulted from the sustainable viability and elongated
HGF secretion of MSCs in the local lesions was due to fi-
brin glue compounding, which significantly improved the
efficiency of treatment with MSCs. Effects of longer sur-
vival time in vivo could be observed as early as 4 weeks
and last to 8 weeks which assured the stable and longer
secretion of HGF by MSCs to improve the bone marrow
microenvironment and promote proliferation and differ-
entiation of themselves as well as other cells in the fem-
oral head, thereby promoting amelioration of ANFH.
Our previous results demonstrated HGF-dosage-dependent
regulation of the downstream signaling pathway medi-
ated by c-Met, the HGF receptor, to regulate the cell fate
of MSCs in vitro and in vivo [22]. Local high expression of
HGF (about 100 nM) which appeared within 2 weeks after
transplantation of HGF-transgenic MSCs preferred to ac-
tivate ERK signaling and in turn promote cell prolifera-
tion, In contrast, local lower expression of HGF, about
20 nM appearing after 2 weeks after MSC transplantation
tended to activate Akt signaling which improved the
osteogenic differentiation of MSCs [22]. In this study, sig-
nificant decrease of activated ERK and Akt signaling could
be observed in vivo in uncompounded MSC-transplanted
ANFH animal models. Loss of ERK caused by the quick
decrease in the level of HGF just like what we observed
in previous studies [22]. The significant downregulation
of Akt activation further indicated the relatively quick
loss of the osteogenic capacity of MSCs in the local re-
gion. However, the higher expression levels of ERK and
Akt in the MSCs + FG group were maintained for arelatively longer period than the MSCs group. Fibrin
glue-compounded MSCs showed dramatically-extended
survivability and prolonged secretion of HGF which
promoted the proliferation and the following osteo-
genic differentiation of MSCs in vivo than uncompound
MSCs. Thus more MSCs with enough time to fully dif-
ferentiate into osteoblasts provided sufficient thera-
peutic cells for ANFH lesion repairing. These results
proposed the important role of fibrin glue in supporting
the HGF-secreting MSCs in the local lesion region for
sustainable therapeutic goal.
Conclusion
Using MSCs compounded with medical fibrin glue pro-
vides a promising new regime which could greatly im-
prove the efficacy of clinical therapy of ANFH.
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